FROM THE DESK OF THE EDITOR-IN-CHIEF
presented in the 1st week of February,
was passed in mid March 2018 in the Lok
Sabha without discussion as the Govt.
and opposition remained at logger heads
with each other. Approx. Rs. 82 lakh
core income / expenditure plan of the
country was not even debated for a day.
Even the smallest of organisations will
debate and discuss in great details,
their annual income and expenditure
plans for optimum utilization. But our
parliamentarians think otherwise.
The Budget did not really have any
positive provisions for the Pharma
Sector apart from the health insurance
plans and new medical colleges. The
industry is facing challenges to stay
competitive globally, to transit form
generic to branded players and
development of R&D.
Clinical trials has remained a hotly
debated topic across the world and more
so in India. Only 1.4% of global
clinical trials are done in India, while
the country has 16% of the world’s
population and carries 20% disease
burden in the world. With our huge and
diverse genetic pool of population,
chronic diseases, largest number of FDA
approved manufacturing plants outside
the USA, we make the ideal platform for
clinical trials. But, lack of clear
policies and changing regulations along
with social difficulties, considerably
affected the growth of this sector. In
2010, more than 500 clinical trials were
done in India; the number dropped to
less than 200 thereafter. Efforts are
now being made to make the regulations
more rationale and balanced. The
timeline for the approval of clinical
trials research has been reduced by the
Central Drugs Standard Control
Organization. Another important question
is Patient Centricity in Clinical
Trials. Our lead article in this issue
attempts to address the core issues.
Last month the Hon. Supreme Court of
India legalized passive euthanasia by
allowing withdrawal of life support to
patients in permanent vegetative state.
In a historic judgment, the law places
the choice in the hands of the
individual. This judgement brings relief
to thousands of suffering patients and
The recently concluded Asia Pharma Expo
in Dhaka, Bangladesh saw some 600+
exhibitors, over 11000 visitors from 31
countries making it a single point
solution for buyers, sellers and
technology partners. The Pharma Review
has been associated with this event
since the beginning and we once again
had an excellent exhibition.
We congratulate Dr. S. Eswara Reddy on
his appointment as interim Drug
Controller General of India (DCGI).
Prior to this appointment, Dr. Reddy was
serving as Joint Drug Controller of
India, CDSCO, Ministry of Health and
Family Welfare, New Delhi.